Locations:
Search IconSearch
March 17, 2016/Cancer

Innovative Liver Tumor Clinic Unites Specialists, Patients In One Site

Fighting liver cancer, quality of life

16-DDI-160-LiverTumorClinic-CQD-650×450

Cleveland Clinic’s Liver Tumor Clinic is designed to provide leading-edge management and treatment of diverse and complex liver malignancies. Patients have access to a multidisciplinary team of specialists — hepatobiliary and transplant surgeons, hepatologists, oncologists, radiation oncologists, interventional radiologists and specialized nurse coordinators — in a one-stop clinic, eliminating multiple appointments with different physicians at various locations.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

An innovative model

Federico Aucejo, MD, heads the Liver Tumor Clinic, and says the innovative multidisciplinary model allows the elaboration of treatment strategies tailored to each individual patient. The model — based on comprehensive disease evaluations, liver malignancy care paths and Tumor Board consensus — allows delivery of cost/effective individualized therapies. Patients are evaluated and treatment is coordinated in a short timeframe: less than 30 days.

“Physicians review medical records, image studies and laboratory values of all patients who are evaluated through the clinic in one central location. The presence of diverse specialists allows interdisciplinary discussions maximizing the patients’ options,” Dr. Aucejo says. “The concept of articulating value-based multidisciplinary clinics, care paths and tumor boards is evolving, innovative and adapts to the changing physiognomy of healthcare.”

The number of patients diagnosed with liver cancer continues to rise due to a variety of reasons including inefficient cancer screening and surveillance programs and emerging uncontrolled risk factors, Dr. Aucejo says.

Program Highlights:

The Liver Tumor Clinic treats all types of liver cancers including:

  • Hepatocellular carcinoma
  • Cholangiocarcinoma
  • Liver metastasis from colorectal cancer
  • Liver metastasis from neuroendocrine tumors
  • Gallbladder cancer
  • Others

Treatment options include diverse surgical interventions, and locoregional and medical oncological therapies only offered by the most highly specialized centers in the nation:

  • Surgical treatments – Extensive liver resections, two-stage hepatectomy, associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) procedure, ex-vivo hepatectomy, liver transplantation, minimally invasive liver surgery via laparoscopic and robotic technology
  • Locoregional treatments – Microwave ablation, cryoablation, electroporation (NanoKnife) and radiofrequency ablation
  • Transcatheter therapies – Radioembolization, chemoembolization
  • Medical oncology treatments – Diverse systemic chemotherapies, molecular targeted therapies, and clinical trials

Advertisement

An immeasurable value

Such a multidisciplinary approach is invaluable to patients with liver cancers, says Cleveland Clinic oncologist Bassam Estfan, MD.

“Having such a resource at our disposal is an extremely valuable tool for optimal care for the increasingly complex and challenging cases we see,” Dr. Estfan says. “Shared clinic visits allow the team to discuss care as viewed from different vantage points. The cumulative multispecialty expertise allows piecing together different aspects of treatment and management to form a comprehensive care plan that is unique to every patient.”

Innovative discoveries

Innovation and treatment discoveries are pivotal within the mission of Cleveland Clinic’s Liver Tumor Clinic. Some of these endeavors include:

  • 3-D printing of liver models and computer software to aid surgical treatments of complex liver malignancies
  • Tissue, serum and breath bio-repository for translational research
  • Liver malignancy mice Xenograft research platform to study liver tumors from individual patients fostering personalized medicine in the field of liver oncology

For questions, contact Dr. Aucejo at aucejof@ccf.org. Refer a patient by calling 855.REFER.123.

Advertisement

Related Articles

Dr. Shahzad Raza
December 18, 2024/Cancer/News & Insight
Researchers Explore Prognostic Value of Transcriptomic Data in Multiple Myeloma

Prediction and bioinformatic data could prove valuable for therapeutic interventions targeting this malignancy

3D rendering of bispecific antibodies
December 17, 2024/Cancer/Blood Cancers
Efficacy and Safety Outcomes of Bispecific Antibodies

Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma

rendering of Doxorubicin molecules
December 13, 2024/Cancer/News & Insight
Research Offers Further Insight into Chemo Scheduling for Early Breast Cancer

Phase 3 trial found no survival differences between weekly or biweekly doxorubicin/cyclophosphamide or between weekly or biweekly paclitaxel

BRCA1 (3d structure)
December 12, 2024/Cancer/News & Insight
Risk-Reducing Surgeries Improve Survival for Younger BRCA Breast Cancer Patients

Findings strengthen evidence for risk-reducing procedures

Acute myeloid leukemia
December 10, 2024/Cancer/Blood Cancers
Access Barriers to Transplant Affect Outcomes in AML

Socioeconomic disparities have a notable influence on access to allogeneic hematopoietic cell transplant

CAR T-cell therapy
December 9, 2024/Cancer/News & Insight
Major Study Finds CAR T-Cell Therapy Safe and Effective for Older Patients With B-Cell Acute Lymphoblastic Leukemia

Offers a new option for patients 60 and older with relapsed/refractory disease

Ad